Denmark's Novo Nordisk on Monday said it has agreed to buy Cardior Pharmaceuticals for up to 1.03 billion euros ($1.11 billion) to strengthen its cardiovascular pipeline. The acquisition is in line with the Danish drugmaker's aim to expand its focus on diabetes and weight-loss therapies to include cardiovascular disease treatments. The deal includes Cardior's lead compound CDR132L, currently in phase 2 clinical development for the treatment of heart failure, Novo said.
Read full NASCAR article on Yahoo Sports
Read all NASCAR articles